High-Content Screens for Huntington's Disease Suppressors
Author Information
Author(s): Joost Schulte, Katharine J. Sepp, Chaohong Wu, Pengyu Hong, J. Troy Littleton
Primary Institution: Massachusetts Institute of Technology
Hypothesis
To identify Huntington's Disease therapeutics, we conducted high-content small molecule and RNAi suppressor screens using a Drosophila primary neural culture Huntingtin model.
Conclusion
The study identified several compounds and a gene that can suppress mutant Huntingtin-induced neurotoxicity in a Drosophila model of Huntington's Disease.
Supporting Evidence
- Four novel drugs were identified as strong suppressors of mutant Huntingtin-induced neurotoxicity.
- Compounds previously found to be effective aggregation inhibitors in mammalian systems were also effective in Drosophila primary cultures.
- Lkb1, an upstream kinase in the mTOR/Insulin pathway, was identified as a suppressor of mutant Huntingtin toxicity.
Takeaway
Researchers looked for ways to help people with Huntington's Disease by testing different drugs and genes in fruit flies, finding some that could help reduce the disease's harmful effects.
Methodology
The study used high-content small molecule and RNAi screens in Drosophila primary neural cultures to identify suppressors of Huntington's Disease toxicity.
Limitations
The study did not observe a direct correlation between the ability of a compound or gene knockdown to suppress aggregate formation and its ability to rescue dysmorphic neurites.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website